Methylation of p16 gene in hematological malignancies
- Author:
Wenming CHEN
1
;
Jiazhi ZHU
;
Jingzhong LIU
;
Shuzhen TAN
Author Information
1. Beijing Red Cross Chaoyang Hospital Affiliated to Capital University of Medical Sciences
- From:
Chinese Medical Journal
1998;111(11):1028-1030
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the incidence of p16 gene methylation in hematological malignancies, and the relations between p16 gene methylation and the prognosis of hematological malignancies. Methods Fifty-five patients were studied by restriction enzyme polymerase chain reaction (PCR) to detect p16 gene methylation. Results p16 gene methylation was detected in 6 of 55 patients (10.9%), who were 1 patient with M2a, 1 patient with M5a, 2 patients with chronic myelogenous leukemia (CML) in blast crisis, 1 patient with progressing multiple myeloma (MM), 1 with non-Hogkin's lymphoma(NHL) accompanied by B-ALL, respectively. p16 gene methylation correlates with adverse prognostic features. The patients with p16 gene methylation had poor response to therapy, and died shortly after p16 gene methylation was detected. Conclusion The methylation of p16 gene plays an improtant role in the pathogenesis and the development of some hematological malignancies. The patients with p16 gene methylation have poor prognosis. The detection of p16 gene is a useful tool for evaluating prognosis of hematological malignancies.
